Literature DB >> 17932957

Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset.

Marc Bitoun1, Jorge A Bevilacqua, Bernard Prudhon, Svetlana Maugenre, Ana Lia Taratuto, Soledad Monges, Fabiana Lubieniecki, Claude Cances, Emmanuelle Uro-Coste, Michèle Mayer, Michel Fardeau, Norma B Romero, Pascale Guicheney.   

Abstract

We report four heterozygous dynamin 2 (DNM2) mutations in five centronuclear myopathy patients aged 1 to 15 years. They all presented with neonatal hypotonia with weak suckling. Thereafter, their phenotype progressively improved. All patients demonstrated muscle weakness prominent in the lower limbs, and most of them also presented with facial weakness, open mouth, arched palate, ptosis, and ophthalmoparesis. Electrophysiology showed only myopathic changes, and muscle biopsies showed central nuclei and type 1 fiber hypotrophy and predominance. Our results expand the phenotypic spectrum of dynamin 2-related centronuclear myopathy from the classic mild form to the more severe neonatal phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932957     DOI: 10.1002/ana.21235

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  55 in total

1.  Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness.

Authors:  Belinda S Cowling; Anne Toussaint; Leonela Amoasii; Pascale Koebel; Arnaud Ferry; Laurianne Davignon; Ichizo Nishino; Jean-Louis Mandel; Jocelyn Laporte
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Clinical utility gene card for: Centronuclear and myotubular myopathies.

Authors:  Valérie Biancalana; Alan H Beggs; Soma Das; Heinz Jungbluth; Wolfram Kress; Ichizo Nishino; Kathryn North; Norma B Romero; Jocelyn Laporte
Journal:  Eur J Hum Genet       Date:  2012-05-23       Impact factor: 4.246

3.  Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations.

Authors:  F Hanisch; T Müller; A Dietz; M Bitoun; W Kress; J Weis; G Stoltenburg; S Zierz
Journal:  J Neurol       Date:  2011-01-09       Impact factor: 4.849

4.  Mice lacking microRNA 133a develop dynamin 2–dependent centronuclear myopathy.

Authors:  Ning Liu; Svetlana Bezprozvannaya; John M Shelton; Madlyn I Frisard; Matthew W Hulver; Ryan P McMillan; Yaru Wu; Kevin A Voelker; Robert W Grange; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

5.  Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers.

Authors:  Lei Wang; Barbara Barylko; Christopher Byers; Justin A Ross; David M Jameson; Joseph P Albanesi
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

6.  Consensus statement on standard of care for congenital myopathies.

Authors:  Ching H Wang; James J Dowling; Kathryn North; Mary K Schroth; Thomas Sejersen; Frederic Shapiro; Jonathan Bellini; Hali Weiss; Marc Guillet; Kimberly Amburgey; Susan Apkon; Enrico Bertini; Carsten Bonnemann; Nigel Clarke; Anne M Connolly; Brigitte Estournet-Mathiaud; Dominic Fitzgerald; Julaine M Florence; Richard Gee; Juliana Gurgel-Giannetti; Allan M Glanzman; Brittany Hofmeister; Heinz Jungbluth; Anastassios C Koumbourlis; Nigel G Laing; Marion Main; Leslie A Morrison; Craig Munns; Kristy Rose; Pamela M Schuler; Caroline Sewry; Kari Storhaug; Mariz Vainzof; Nanci Yuan
Journal:  J Child Neurol       Date:  2012-03       Impact factor: 1.987

7.  Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.

Authors:  Johann Böhm; Valérie Biancalana; Elizabeth T Dechene; Marc Bitoun; Christopher R Pierson; Elise Schaefer; Hatice Karasoy; Melissa A Dempsey; Fabrice Klein; Nicolas Dondaine; Christine Kretz; Nicolas Haumesser; Claire Poirson; Anne Toussaint; Rebecca S Greenleaf; Melissa A Barger; Lane J Mahoney; Peter B Kang; Edmar Zanoteli; John Vissing; Nanna Witting; Andoni Echaniz-Laguna; Carina Wallgren-Pettersson; James Dowling; Luciano Merlini; Anders Oldfors; Lilian Bomme Ousager; Judith Melki; Amanda Krause; Christina Jern; Acary S B Oliveira; Florence Petit; Aurélia Jacquette; Annabelle Chaussenot; David Mowat; Bruno Leheup; Michele Cristofano; Juan José Poza Aldea; Fabrice Michel; Alain Furby; Jose E Barcena Llona; Rudy Van Coster; Enrico Bertini; Jon Andoni Urtizberea; Valérie Drouin-Garraud; Christophe Béroud; Bernard Prudhon; Melanie Bedford; Katherine Mathews; Lori A H Erby; Stephen A Smith; Jennifer Roggenbuck; Carol A Crowe; Allison Brennan Spitale; Sheila C Johal; Anthony A Amato; Laurie A Demmer; Jessica Jonas; Basil T Darras; Thomas D Bird; Mercy Laurino; Selman I Welt; Cynthia Trotter; Pascale Guicheney; Soma Das; Jean-Louis Mandel; Alan H Beggs; Jocelyn Laporte
Journal:  Hum Mutat       Date:  2012-04-04       Impact factor: 4.878

Review 8.  Congenital myopathies: an update.

Authors:  Jessica R Nance; James J Dowling; Elizabeth M Gibbs; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

9.  Clinical and Pathological Features of Korean Patients with DNM2-Related Centronuclear Myopathy.

Authors:  Young-Eun Park; Young-Chul Choi; Jong-Suk Bae; Chang-Hoon Lee; Hyang-Suk Kim; Jin-Hong Shin; Dae-Seong Kim
Journal:  J Clin Neurol       Date:  2014-01-06       Impact factor: 3.077

10.  Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy.

Authors:  Elizabeth M Gibbs; Nigel F Clarke; Kristy Rose; Emily C Oates; Richard Webster; Eva L Feldman; James J Dowling
Journal:  J Mol Med (Berl)       Date:  2013-01-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.